Semaglutide vs Tirzepatide for Weight Loss

If your only question is “which one will help me lose more weight,” there is now a real answer from a real trial — and then there is the more useful, more honest version of that answer. This page is the weight-loss-focused comparison. For the broader head-to-head that also covers cardiovascular and sleep-apnea differences, mechanism, and the brand map, see semaglutide vs tirzepatide. Here the lens is narrow: losing weight, and nothing else.

What the head-to-head trial actually showed

For years the two drugs were compared only indirectly, by lining up separate trials. That changed with SURMOUNT-5, the first direct head-to-head study, published in The New England Journal of Medicine. It randomly assigned 751 adults with obesity (and at least one weight-related condition, but without type 2 diabetes) to the maximum tolerated dose of either tirzepatide or semaglutide for 72 weeks.

The result was clear: tirzepatide produced a mean weight loss of about 20.2%, versus about 13.7% for semaglutide — roughly 7.8 kg more on average, and a meaningfully larger reduction in waist circumference. The difference also showed up at the high end: about 31.6% of the tirzepatide group lost a quarter or more of their body weight, compared with about 16.1% on semaglutide. On every weight-related endpoint measured, tirzepatide came out ahead.

That is the headline, and it is genuine. But two things matter before you treat it as the whole story.

The 2026 picture is narrowing

SURMOUNT-5 compared tirzepatide against semaglutide at its then-standard maximum of 2.4 mg. In March 2026 the FDA approved a higher-dose Wegovy HD (semaglutide 7.2 mg), based on the STEP UP trial. At that dose, mean weight loss came in around 19-21% over 72 weeks, with roughly one in three participants losing 25% or more — numbers that sit much closer to tirzepatide’s than the older 2.4 mg figures did.

So the gap that SURMOUNT-5 captured is not fixed. At the highest available doses, semaglutide closes much of the headline distance. The trade-off is tolerability: the 7.2 mg dose came with more gastrointestinal side effects and a notably higher rate of dysesthesia (altered skin sensation) than the 2.4 mg dose. Wegovy HD is positioned as a step for people who tolerated 2.4 mg but want more weight loss, not as a routine starting point. The practical takeaway is that “tirzepatide loses more” is a true statement about averages at specific doses, not a fixed law — and the menu of options keeps shifting.

Trial averages vs what you’ll actually lose

The bigger caveat applies to both drugs equally, and it is the single most important thing to understand before choosing between them: trial numbers are best-case averages from a controlled setting, and real-world results are lower.

A 2025 Cleveland Clinic analysis of nearly 8,000 patients found average weight loss of about 8.7% at one year — well below the trial figures for either drug. The reason was not that the medications stopped working. It was that many people discontinued early or never reached the top dose: in that cohort, more than 80% were on lower maintenance doses, and only about half were still on treatment after a year. Among the people who stayed on treatment, average loss was closer to 11.9%; those who stopped within three months lost only about 3.6%.

Why this matters for choosing: the on-paper advantage of one drug over the other shrinks when persistence and dose are the real bottleneck. A medication that delivers 20% in a trial but that you stop after two months because of nausea will lose to one you can actually live with. For most people, the decisive variable isn’t which molecule is theoretically stronger — it’s which one they can tolerate, afford, and stay on long enough to reach a meaningful dose.

Tolerability and reaching the weight-loss dose

Both drugs work the same way you’ll feel it: by reducing appetite and slowing digestion, which produces the same family of side effects — nausea, vomiting, constipation, diarrhoea — most common during the gradual dose-escalation phase. In SURMOUNT-5 the safety profiles were broadly similar, with gastrointestinal events most common in both groups and comparable discontinuation for side effects.

There are some differences worth knowing. Tirzepatide acts on two gut-hormone pathways rather than one, and some people find one drug sits better with them than the other for reasons that aren’t fully predictable in advance. The higher-dose 7.2 mg semaglutide introduced more dysesthesia. Neither drug’s side-effect profile is a clean tiebreaker; the honest position is that tolerability is individual, often only revealed by trying, and best managed by titrating slowly under a prescriber’s guidance. This page does not give dosing schedules — escalation is set and adjusted by your clinician. For the details on managing side effects, see semaglutide side effects and tirzepatide side effects.

Cost and access for weight loss specifically

For weight loss, both are FDA-approved as brand products: Wegovy (semaglutide) and Zepbound (tirzepatide). The diabetes-branded versions — Ozempic and Mounjaro — are the same molecules but are approved for type 2 diabetes, so using them purely for weight loss is off-label and usually not covered for that purpose. If your goal is weight loss, the weight-management brand is the relevant one.

Cost is frequently the real decider, and it is not a fixed gap between the two. Both manufacturers run cash-pay programs, insurance coverage varies enormously by plan, and prices change. Because the numbers move and depend heavily on your coverage, this page keeps them light and points you to the dedicated breakdowns: see semaglutide for weight loss and tirzepatide for weight loss for the per-drug picture, and the GLP-1 weight-loss guide for how brand, indication, and coverage interact. The short version: for many people, what their plan covers will matter more to the final outcome than the few percentage points separating the two drugs in a trial.

Note: Neither of these is a self-supply decision. Both are prescription drugs that require a clinician’s evaluation, and the gray-market “research” versions sold online are a different and riskier product, not a cheaper version of the same thing.

So which should you pick for weight loss?

If the only input were the trial average, tirzepatide wins — it produced more weight loss head-to-head, and more people hit the largest milestones. That’s a fair default starting point to discuss with a prescriber, especially if substantial weight loss is the primary goal.

But “wins on average” is not the same as “right for you.” Semaglutide is a reasonable, evidence-backed choice, particularly given the new higher dose that narrows the efficacy gap, a longer real-world track record, and weight-loss-relevant cardiovascular evidence behind the Wegovy brand. And the factors that most often determine whether someone actually loses weight — tolerability, cost, coverage, and staying on treatment long enough to reach an effective dose — frequently point to a different answer than the trial leaderboard does.

The genuinely useful framing is this: pick the medication you can stay on. That is an individual decision a licensed prescriber makes with you, weighing your health profile, what your insurance covers, and how your body responds. Switching between the two later is common if the first choice doesn’t deliver or doesn’t agree with you. The headline number is a starting point for that conversation, not the end of it.